New drug trial aims to control blood cancer with daily pill
NCT ID NCT00254423
Summary
This study tested whether a daily pill called dasatinib could control Chronic Myelogenous Leukemia (CML) in its early, chronic phase. It involved 150 patients who were newly diagnosed or had minimal prior treatment. The main goal was to see if the drug could achieve a deep reduction in leukemia cells after one year, while closely monitoring safety and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.